# Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

> **NCT05681039** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (estimated)

## Conditions studied

- Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tiragolumab
- **DRUG:** Atezolizumab
- **BEHAVIORAL:** Standard of Care
- **BEHAVIORAL:** Questionnaires
- **RADIATION:** Cisplatin
- **RADIATION:** Carboplatin

## Key facts

- **NCT ID:** NCT05681039
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-02
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05681039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05681039, "Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05681039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*